Bulk Pharmaceutical API Sources for NITROFURANTOIN, MACROCRYSTALLINE

Bulk Pharmaceutical API Sources for NITROFURANTOIN, MACROCRYSTALLINE

Vendor	Vendor Homepage	Vendor Sku	API Url
ChemBridge		5492202
Sigma-Aldrich		N7878_SIGMA
NovoSeek		6604200
ISpharm		I07-0015
MolPort		MolPort-001-018-217
NIH Clinical Collection		SAM002554913
AKos Consulting & Solutions		AKOS001678301

Nitrofurantoin Macrocrystalline API Sourcing: Key Manufacturers and Patent Landscape

Last updated: February 19, 2026

This report analyzes the global supply chain for nitrofurantoin macrocrystalline bulk active pharmaceutical ingredient (API), focusing on primary manufacturers, production capacities, and relevant patent expirations. The analysis identifies key players in API production and assesses potential supply chain vulnerabilities and opportunities.

What is Nitrofurantoin Macrocrystalline?

Nitrofurantoin macrocrystalline is an antibiotic used primarily to treat urinary tract infections (UTIs). It is a granular, less soluble form of nitrofurantoin, which allows for slower release and potentially reduced gastrointestinal side effects compared to the monohydrate form. The macrocrystalline form is typically administered in higher doses and less frequently. Its mechanism of action involves bacterial protein synthesis inhibition and damage to bacterial DNA, RNA, and cell wall synthesis.

Global API Production Landscape

The production of nitrofurantoin macrocrystalline API is concentrated among a limited number of manufacturers, primarily located in Asia, with significant contributions from India and China. These manufacturers are subject to stringent regulatory oversight from bodies such as the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA).

Key global manufacturers of nitrofurantoin macrocrystalline API include:

• Caplin Point Laboratories Ltd. (India)
• Dr. Reddy's Laboratories (India)
• Aurobindo Pharma (India)
• IOL Chemicals and Pharmaceuticals Ltd. (India)
• Anqiu Pharmaceutical Co., Ltd. (China)
• Hebei Tianze Pharmaceutical Co., Ltd. (China)
• Sichuan Clover Biotechnology Co., Ltd. (China)

Table 1: Selected Nitrofurantoin Macrocrystalline API Manufacturers

Manufacturer	Country	Regulatory Approvals (Examples)	Notes
Caplin Point Laboratories Ltd.	India	US DMF, EU CEP	Significant exporter; focuses on emerging markets.
Dr. Reddy's Laboratories	India	US DMF, EU CEP	Large-scale producer with diversified portfolio.
Aurobindo Pharma	India	US DMF, EU CEP	Global presence, strong in generics.
IOL Chemicals and Pharmaceuticals Ltd.	India	US DMF, EU CEP	Vertically integrated; key supplier for various APIs.
Anqiu Pharmaceutical Co., Ltd.	China	US DMF (potential)	Focus on Chinese domestic and export markets.
Hebei Tianze Pharmaceutical Co., Ltd.	China	Chinese GMP	Production for domestic market and specific export channels.
Sichuan Clover Biotechnology Co., Ltd.	China	Chinese GMP	Emerging player with growing capacity.

Source: Company reports, regulatory filings, industry databases.

Production capacity is often not publicly disclosed but is estimated based on market share and product portfolios. Indian manufacturers generally possess higher capacities due to established infrastructure and export focus. Chinese manufacturers are also significant contributors, with increasing adherence to international quality standards.

Regulatory Compliance and Quality Standards

API manufacturers must adhere to Good Manufacturing Practices (GMP). Regulatory filings, such as Drug Master Files (DMFs) in the U.S. and Certificates of Suitability to the European Pharmacopoeia (CEPs) in Europe, are critical for market access. These filings detail the manufacturing process, quality control, and analytical methods used to ensure API purity and consistency.

The U.S. FDA maintains a database of DMFs, which allows generic drug manufacturers to reference the API information without needing to disclose proprietary details. Similarly, CEPs issued by the European Directorate for the Quality of Medicines & HealthCare (EDQM) confirm that the API complies with European Pharmacopoeia standards.

Table 2: Key Regulatory Filings for Nitrofurantoin Macrocrystalline API

Region	Filing Type	Issuing Authority	Significance
United States	DMF	U.S. Food and Drug Administration (FDA)	Required for generic drug applications (ANDA).
Europe	CEP	EDQM	Streamlines regulatory approval for medicines in EU member states.
Japan	MF (Master File)	Pharmaceuticals and Medical Devices Agency (PMDA)	Essential for drug registration in Japan.
India	DMF	Central Drugs Standard Control Organisation (CDSCO)	Facilitates domestic and export product registrations.

Source: FDA, EDQM, industry knowledge.

Patent Landscape and Expirations

The patent landscape for nitrofurantoin macrocrystalline itself is largely historical, as the molecule has been in use for decades. The primary patents protecting the original composition of matter and early manufacturing processes have long expired. However, patents can still be relevant for:

• Novel Manufacturing Processes: New or improved methods of synthesis that offer higher purity, better yields, or lower environmental impact.
• Specific Polymorphs or Crystal Forms: Patents may cover unique crystalline structures of nitrofurantoin macrocrystalline that exhibit improved stability or bioavailability.
• Formulations: Patents on specific finished drug product formulations containing nitrofurantoin macrocrystalline, such as extended-release tablets or specific excipient combinations.

The compound nitrofurantoin was first patented in the 1950s. While the basic compound is off-patent globally, the specific macrocrystalline form or improved manufacturing processes could have been subject to later patenting. However, identifying active, commercially relevant patents specifically on the macro crystalline API manufacturing process, as opposed to its use or formulation, requires detailed patent searching.

Key Patent Expiration Considerations:

• Composition of Matter Patents: Expired. This means the basic chemical entity is generic.
• Process Patents: Potentially active for specific, innovative synthesis routes. If a significant process patent exists for a high-yield or cost-effective method, its expiration can open the market to more manufacturers. However, detailed analysis of patent databases (e.g., USPTO, EPO, WIPO) is necessary to pinpoint such active patents and their expiration dates.
• Polymorph Patents: If a patent covers a specific, advantageous polymorph of nitrofurantoin macrocrystalline, its expiration would allow other manufacturers to produce that form. This is a critical area to monitor for generic entry.

Based on the known history of nitrofurantoin, the fundamental patents have expired. Generic manufacturers typically focus on developing their own non-infringing processes or wait for any remaining process/polymorph patents to expire. The absence of strong, recent patent protection on the core macrocrystalline API manufacturing suggests a competitive generic market, driven by cost and regulatory compliance.

Market Dynamics and Supply Chain Risks

The nitrofurantoin macrocrystalline market is characterized by:

• Generic Competition: High degree of competition among generic drug manufacturers, leading to price pressures.
• API Cost Sensitivity: API cost is a significant component of the finished drug price, making reliable and cost-effective API sourcing paramount.
• Regulatory Scrutiny: API manufacturers face continuous regulatory inspections. Any lapse can lead to import alerts or market withdrawal, impacting supply.
• Geopolitical Factors: Concentration of manufacturing in specific regions (India, China) exposes the supply chain to geopolitical risks, trade disputes, or localized environmental regulations impacting production.
• Quality Issues: A single API manufacturer facing quality issues or recalls can lead to significant supply disruptions for multiple finished drug product companies.

Potential Supply Chain Risks:

1. Single-Sourcing Reliance: Dependence on a limited number of API suppliers for the macrocrystalline form.
2. Regulatory Non-Compliance: A major supplier failing FDA or EMA inspections.
3. Raw Material Shortages: Disruptions in the supply of key starting materials for nitrofurantoin synthesis.
4. Environmental Regulations: Stricter enforcement of environmental laws in manufacturing regions can impact production volumes or costs.

Companies relying on nitrofurantoin macrocrystalline API should diversify their supplier base and maintain strong relationships with multiple qualified manufacturers. Auditing manufacturing sites and closely monitoring regulatory compliance are essential risk mitigation strategies.

Key Takeaways

• Nitrofurantoin macrocrystalline API production is dominated by manufacturers in India and China, with significant regulatory filings (US DMF, EU CEP) indicating global market access.
• The patent landscape for the basic nitrofurantoin compound is expired. While specific process or polymorph patents might exist, the core API is largely off-patent, fostering a competitive generic market.
• Supply chain risks include over-reliance on a few key manufacturers, potential regulatory non-compliance, and geopolitical factors affecting production hubs.
• Diversifying API suppliers and conducting thorough due diligence on quality and regulatory standing are critical for ensuring consistent supply.

Frequently Asked Questions

1. What is the typical lead time for sourcing bulk nitrofurantoin macrocrystalline API from Asian manufacturers? Lead times generally range from 8 to 16 weeks, depending on the manufacturer's current production schedule, order volume, and existing inventory. Expedited orders may be possible but often incur premium pricing.

2. Are there any known shortages of nitrofurantoin macrocrystalline API in the global market? While specific shortages are not always publicly announced, market intelligence suggests that localized supply constraints can occur due to manufacturing issues or increased demand. No widespread, persistent shortages have been widely reported recently.

3. What are the primary quality control parameters for nitrofurantoin macrocrystalline API? Key parameters include assay (potency), related substances/impurities (e.g., heavy metals, organic impurities), particle size distribution, loss on drying, residue on ignition, and microbial limits. Compliance with USP, EP, or JP pharmacopoeial standards is essential.

4. Can manufacturers use alternative synthesis routes if a specific process patent is still active? Yes, manufacturers can develop and validate novel, non-infringing synthesis routes. This requires significant R&D investment and rigorous analytical characterization to demonstrate equivalence and meet regulatory requirements.

5. What is the typical shelf life of nitrofurantoin macrocrystalline API? The typical shelf life for nitrofurantoin macrocrystalline API, when stored under recommended conditions (e.g., protected from light and moisture), is generally 2 to 5 years. Manufacturers specify exact expiry dates based on stability studies.

---

Citations

[1] U.S. Food and Drug Administration. (n.d.). Drug Master Files. Retrieved from https://www.fda.gov/drugs/drug-master-files/drug-master-files

[2] European Directorate for the Quality of Medicines & HealthCare. (n.d.). Certificates of Suitability (CEP). Retrieved from https://www.edqm.eu/en/certificates-suitability-cep

[3] Caplin Point Laboratories Ltd. (n.d.). Product Portfolio. Retrieved from manufacturer's official website (specific URL not provided as it may change).

[4] Dr. Reddy's Laboratories. (n.d.). API Business. Retrieved from manufacturer's official website (specific URL not provided as it may change).

[5] Aurobindo Pharma. (n.d.). API Business. Retrieved from manufacturer's official website (specific URL not provided as it may change).

[6] IOL Chemicals and Pharmaceuticals Ltd. (n.d.). Product List. Retrieved from manufacturer's official website (specific URL not provided as it may change).

[7] Anqiu Pharmaceutical Co., Ltd. (n.d.). Products. Retrieved from manufacturer's official website (specific URL not provided as it may change).

[8] Hebei Tianze Pharmaceutical Co., Ltd. (n.d.). Product Catalog. Retrieved from manufacturer's official website (specific URL not provided as it may change).

[9] Sichuan Clover Biotechnology Co., Ltd. (n.d.). APIs. Retrieved from manufacturer's official website (specific URL not provided as it may change).